Resumen
Further risk stratification among high-risk renal cell carcinomas is relevant as it helps balance the benefits and drawbacks of adjuvant immunotherapy. The effects of the lung immune prognostic index (LIPI), which is calculated based on the derived neutrophil-to-lymphocyte ratio and lactate dehydrogenase levels, and was evaluated using a retrospective, multi-institutional database. Of the 235 patients with high-risk renal cell carcinoma (=pT3 or N1?2 and M0), 119 (50.6%), 91 (38.7%), and 25 (10.6%) were categorized as good (0), intermediate (1), and poor (2) based on the LIPI score, respectively, and recurrence-free survival (RFS) was significantly correlated with the score groups (median progression-free survival: 90.8 vs. 21.2 vs. 10.0 months). The LIPI was an independent predictor of RFS, and prediction accuracy improved with the addition of the LIPI to preexisting scores. The LIPI can be a useful biomarker for predicting recurrence, particularly for identifying the highest-risk cohorts.